Cargando…

Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies

BACKGROUND AND OBJECTIVE: Saroglitazar is a newer antidiabetic agent approved to manage dyslipidemia. The objective is tevaluate the efficacy and safety profiles of saroglitazar in patients with dyslipidemia. METHODS: A systematic search was conducted using PubMed, Cochrane Library, Scopus, and Goog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chhabra, Manik, Vidyasagar, Kota, Gudi, Sai Krishna, Sharma, Jatin, Sharma, Rishabh, Rashid, Muhammed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249226/ https://www.ncbi.nlm.nih.gov/pubmed/35776741 http://dx.doi.org/10.1371/journal.pone.0269531

Ejemplares similares

Potentially Inappropriate Medication Use in Older Hospitalized Patients with Type 2 Diabetes: A Cross-Sectional Study
por: Sharma, Rishabh, et al.
Publicado: (2020)

Prevalence of Polypharmacy, Hyperpolypharmacy and Potentially Inappropriate Medication Use in Older Adults in India: A Systematic Review and Meta-Analysis
por: Bhagavathula, Akshaya S., et al.
Publicado: (2021)

Assessment of Knowledge on Risk Factors, Warning Signs, and Early Treatment Approaches of Stroke among Community Adults in North India: A Telephone Interview Survey
por: Chhabra, Manik, et al.
Publicado: (2019)

Prevalence and Predictors of Self-Medication Practices in India:  A Systematic Literature Review and Meta-Analysis
por: Rashid, Muhammed, et al.
Publicado: (2020)

Impact of pharmacist-led home medicines review services on drug-related problems among the elderly population: a systematic review
por: Gudi, Sai Krishna, et al.
Publicado: (2019)

Knowledge and attitude towards HIV/AIDS in India: A systematic review and meta-analysis of 47 studies from 2010-2020
por: Bhagavathula, Akshaya Srikanth, et al.
Publicado: (2021)

Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer Who Underwent Orchiectomy: A Systematic Review and Meta-analysis
por: Rashid, Muhammed, et al.
Publicado: (2019)

Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study
por: Goyal, Omesh, et al.
Publicado: (2020)

Significant Reduction of Elevated Triglycerides and Liver Fibrosis in Diabetic Dyslipidemia with Saroglitazar: A Case Report
por: Roy, Sayak, et al.
Publicado: (2019)

Knowledge and beliefs towards universal safety precautions during the coronavirus disease (COVID-19) pandemic among the Indian public: a web-based cross-sectional survey
por: Gudi, Sai Krishna, et al.
Publicado: (2020)

A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)
por: Pai, Vikas, et al.
Publicado: (2014)

Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL/6J mice
por: Kumari, Deepika, et al.
Publicado: (2023)

The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis
por: Santenna, Chenchula, et al.
Publicado: (2021)

A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis
por: Vuppalanchi, Raj, et al.
Publicado: (2021)

Global prevalence and effect of comorbidities and smoking status on severity and mortality of COVID-19 in association with age and gender: a systematic review, meta-analysis and meta-regression
por: Chenchula, Santenna, et al.
Publicado: (2023)

Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]
por: Shuja, Syed Hasan, et al.
Publicado: (2021)

Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience
por: Roy, Sayak
Publicado: (2020)

Efficacy and safety of rosuvastatin in the management of dyslipidemia
por: Rubba, Paolo, et al.
Publicado: (2009)

A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy
por: Deshpande, Alka, et al.
Publicado: (2016)

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
por: Kaul, Upendra, et al.
Publicado: (2019)

Knowledge, attitude, and practice of medical interns and postgraduate residents on American Geriatric Society updated Beers criteria
por: Rathore, Aditi, et al.
Publicado: (2023)

Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence
por: Sosale, Aravind, et al.
Publicado: (2015)

Meta-analysis of the Efficacy and Safety of Adjunctive Rosuvastatin for Dyslipidemia in Patients with Schizophrenia
por: UNGVARI, Gabor S., et al.
Publicado: (2018)

Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials
por: Bhagavathula, Akshaya Srikanth, et al.
Publicado: (2021)

Deciphering the Precise Target for Saroglitazar Associated Antiangiogenic Effect: A Computational Synergistic Approach
por: Dabral, Swarna, et al.
Publicado: (2023)

Efficacy and safety of saroglitazar in real‐world patients of non‐alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience
por: Chaudhuri, Sujit, et al.
Publicado: (2023)

Saroglitazar in Non-alcoholic Fatty Liver Disease From Bench to Bedside: A Comprehensive Review and Sub-group Meta-Analysis
por: Roy, Akash, et al.
Publicado: (2023)

Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes
por: Chatterjee, Sanjay, et al.
Publicado: (2015)

Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial
por: Rodriguez-Gutierrez, Rene, et al.
Publicado: (2022)

Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis
por: Ida, Satoshi, et al.
Publicado: (2019)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Tafenoquine for Plasmodium vivax malaria: Concerns regarding efficacy & safety
por: Sharma, Jatin, et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
por: Jani, Rajendra H., et al.
Publicado: (2013)

Eating speed and the risk of type 2 diabetes: explorations based on real-world evidence
por: Gudi, Sai Krishna
Publicado: (2020)

Erratum: Eating speed and the risk of type 2 diabetes: explorations based on real-world evidence
por: Gudi, Sai Krishna
Publicado: (2020)

Dairy consumption and risk of type-2 diabetes: the untold story
por: Gudi, Sai Krishna
Publicado: (2021)

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis
por: Akbari, Rasoul, et al.
Publicado: (2021)

Dyslipidemia and Breast Cancer
por: Aggarwal, Neelam, et al.
Publicado: (2018)

Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia
por: Kota, Sunil K., et al.
Publicado: (2013)

Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia
por: Vissers, Maud N., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_dcd4k0rncn4hoh0ge3j5hgq8gt